Heparin-induced thrombocytopenia: A frequent complication after cardiac surgery

Archives des Maladies du Coeur et des Vaisseaux

Volumn 100, Issue 6-7, 2007, Pages 563-568

  Pouplard, C ^a   Regina, S ^a   May, M A ^a   Gruel, Yves ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBODY; ARGATROBAN; CLOPIDOGREL; DANAPAROID; FONDAPARINUX; HEPARIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN G1; LEPIRUDIN; THROMBOCYTE FACTOR 4;

ANAPHYLACTIC SHOCK; ANTIBODY PRODUCTION; ANTICOAGULATION; ARTICLE; BLEEDING; BLOOD CLOTTING; CARDIOPULMONARY BYPASS; DIAGNOSTIC TEST; DRUG WITHDRAWAL; HEART SURGERY; HUMAN; IMMUNOASSAY; IMMUNOGENICITY; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; CARDIAC SURGICAL PROCEDURES; CHONDROITIN SULFATES; DERMATAN SULFATE; HEPARIN; HEPARINOIDS; HEPARITIN SULFATE; HIRUDINS; HUMANS; IMMUNOGLOBULIN G; PLATELET FACTOR 4; POSTOPERATIVE COMPLICATIONS; RECOMBINANT PROTEINS; THROMBOCYTOPENIA;

EID: 34547739664     PISSN: 00039683     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Warkentin TE. Heparin-induced thrombocytopenia: pathogenesis and management. Br J Haematol 2003; 121 (4): 535-55.
2. Greinacher A. Heparin-induced thrombocytopenia: frequency and pathogenesis. Pathophysiol Haemost Thromb 2006; 35: 37-45.
3. Gruel Y, Regina S, Pouplard C. Heparin-induced thrombocytopenia. Rev Prat 2006; 56 (7): 710-8.
4. Gruel Y, Pouplard C, Nguyen P, Borg JY, Derlon A, Juhan-Vague I, Regnault V, Samama M. Biological and clinical features of low-molecular-weight heparin-induced thrombocytopenia. Br J Haematol 2003; 121 (5): 786-92.
5. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. Blood 2005; 106 (8): 2710-5.
6. Prandoni P, Siragusa S, Girolami B, Fabris F. The incidence of heparin-induced thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 2005; 106 (9): 3049-54.
7. Warkentin TE, Sheppard JA, Horsewood P, Simpson PJ, Moore JC, Kelton JG. Impact of the patient population on the risk for heparin-induced thrombocytopenia. Blood 2000; 96 (5): 1703-8.
8. Amiral J, Bridey F, Dreyfus M, Vissac A, Fressinaud E, Wolf M, Meyer D. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thrombosis and Haemostasis 1992; 68 (1): 95-6.
9. Rauova L, Poncz M, McKenzie SE, Reilly MP, Arepally G, Weisel JW, Nagaswami C, Cines DB, Sachais BS. Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. Blood 2005; 105 (1): 131-8.
10. Greinacher A, Gopinadhan M, Gunther JU, Omer-Adam MA, Strobel U, Warkentin TE, Papastavrou G, Weitschies W, Helm CA. Close approximation of two platelet factor 4 tetramers by charge neutralization forms the antigens recognized by HIT antibodies. Arterioscler Thromb Vasc Biol 2006; 26 (10): 2386-93.
11. Warkentin TE. Clinical picture of Heparin-induced Thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced Thrombocytopenia. Third ed. New York-Basel: Marcel Dekker, Inc; 2004. p. 53-106.
12. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. AnnThorac Surg 2003; 76 (2): 638-48.
13. Trossaert M, Gaillard A, Commin PL, Amiral J, Vissac AM. High incidence of anti-heparin/platelet factor 4 antibodies after cardiopulmonary bypass surgery. Br J Haematol 1998; 101 (4): 653-655.
14. Pouplard C, May MA, Iochmann S, Amiral J, Vissac AM, Marchand M, Gruel Y. Antibodies to platelet factor 4 - Heparin after cardiopulmonary bypass in patients anticoagulated with unfractionated heparin or a low-molecular-weight heparin - Clinical implications for heparin-induced thrombocytopenia. Circulation 1999; 99 (19): 2530-2536.
15. Pouplard C, May M, Regina S, Maakaroun A, Fusciardi J, Gruel Y. Changes in the platelet count after cardiopulmonary bypass can efficiently predict the development of pathogenic heparin-dependent antibodies. Blood 2002; abstract (100): 16a-17a.
16. Pouplard C, May MA, Regina S, Marchand M, Fusciardi J, Gruel Y. Changes in platelet count after cardiac surgery can effectively predict the development of pathogenic heparin-dependent antibodies. Br J Haematol 2005; 128 (6): 837-41.
17. Trikalinos TA, Karassa FB, Ioannidis JP. Meta-analysis of the association between low-affinity Fcgamma receptor gene polymorphisms and hematologic and autoimmune disease. Blood 2001; 98 (5): 1634-5.
18. Gruel Y, Pouplard C, Lasne D, Magdelaine-Beuzelin C, Charroing C, Watier H. The homozygous FcgammaRIIIa-158V genotype is a risk factor for heparin-induced thrombocytopenia in patients with antibodies to heparin-platelet factor 4 complexes. Blood 2004; 104 (9): 2791-3.
19. Smith B, Rinder H, Rinder C. Cardiopulmonary bypass. In: Michelson AD, editor. Platelets. San Diego: Academic Press; 2006. p. 1077-1095.
20. Matthai WH, Jr. Thrombocytopenia in cardiovascular patients: diagnosis and management. Chest 2005; 127 (2 Suppl): 46S-52S.
21. Scirica BM, Cannon CP, Cooper R, Aster RH, Brassard J, McCabe CH, Charlesworth A, Skene AM, Braunwald E. Drug-induced thrombocytopenia and thrombosis: evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial. J Thromb Thrombolysis 2006; 22 (2): 95-102.
22. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126 (3 Suppl): 311S-337S.
23. Arepally GM, Ortel TL. Clinical practice. Heparin-induced thrombocytopenia. N Engl J Med 2006; 355 (8): 809-17.
24. Warkentin TE. Think of HIT when thrombosis follows heparin. Chest 2006; 130 (3): 631-2.
25. Warkentin TE. Heparin-induced thrombocytopenia: diagnosis and management. Circulation 2004; 110 (18): e454-8.
26. Lillo-Le Louet A, Boutouyrie P, Alhenc-Gelas M, Le Beller C, Gautier I, Aiach M, Lasne D. Diagnostic score for heparin-induced thrombocytopenia after cardiopulmonary bypass. J Thromb Haemost 2004; 2 (11): 1882-8.
27. Pouplard C, Amiral J, Borg JY, Laporte-Simitsidis S, Delahousse B, Gruel Y. Decision analysis for use of platelet aggregation test, carbon 14 serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. American Journal of Clinical Pathology 1999; 111 (5): 700-706.
28. de Maistre E, Gruel Y, Lasne D. Diagnosis and management of heparin-induced thrombocytopenia. Can J Anaesth 2006; 53 (6 Suppl): S123-34.
29. Warkentin TE, Sheppard JA, Moore JC, Moore KM, Sigouin CS, Kelton JG. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia: how much class do we need? J Lab Clin Med 2005; 146 (6): 341-6.
30. Risch L, Bertschmann W, Heijnen IA, Huber AR. A differentiated approach to assess the diagnostic usefulness of a rapid particle gel immunoassay for the detection of antibodies against heparin-platelet factor 4 in cardiac surgery patients. Blood Coagul Fibrinolysis 2003; 14 (1): 99-106.
31. Keeling D, Davidson S, Watson H. The management of heparin-induced thrombocytopenia. Br J Haematol 2006; 133 (3): 259-69.
32. Magnani HN, Gallus A. Heparin-induced thrombocytopenia (HIT). A report of 1,478 clinical outcomes of patients treated with danaparoid (Orgaran) from 1982 to mid-2004. Thromb Haemost 2006; 95 (6): 967-81.
33. Tardy B, Lecompte T, Boelhen F, Tardy-Poncet B, Elalamy I, Morange P, Gruel Y, Wolf M, Francois D, Racadot E, Camarasa P, Blouch MT, Nguyen F, Doubine S, Dutrillaux F, Alhenc-Gelas M, Martin-Toutain I, Bauters A, Ffrench P, de Maistre E, Grunebaum L, Mouton C, Huisse MG, Gouault-Heilmann M, Lucke V. Predictive factors for thrombosis and major bleeding in an observational study in 181 patients with heparin-induced thrombocytopenia treated with lepirudin. Blood 2006; 108 (5): 1492-6.
34. Greinacher A, Eichler P, Albrecht D, Strobel U, Potzsch B, Eriksson BI. Antihirudin antibodies following low-dose subcutaneous treatment with desirudin for thrombosis prophylaxis after hip-replacement surgery: incidence and clinical relevance. Blood 2003; 101 (7): 2617-9.
35. Matthai WH, Jr. Safety and efficacy of argatroban in patients with heparin-induced thrombocytopenia. Curr Hematol Rep 2006; 5 (1): 95-9.
36. Spinler SA. New concepts in heparin-induced thrombocytopenia: diagnosis and management. J Thromb Thrombolysis 2006; 21 (1): 17-21.